{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T11:38:46Z","timestamp":1776425926022,"version":"3.51.2"},"reference-count":21,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck &amp; Co Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jhltonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Heart and Lung Transplantation"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.healun.2025.08.023","type":"journal-article","created":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T16:28:53Z","timestamp":1757608133000},"page":"148-156","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Tolerability and clinical efficacy of letermovir for primary cytomegalovirus prophylaxis after heart transplantation"],"prefix":"10.1016","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4800-7979","authenticated-orcid":false,"given":"Jennifer K.L.","family":"Chow","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda R.","family":"Vest","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"DeNofrio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David R.","family":"Snydman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.healun.2025.08.023_bib1","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.transproceed.2011.02.069","article-title":"Update and review: state-of-the-art management of cytomegalovirus infection and disease following thoracic organ transplantation","volume":"43","author":"Snydman","year":"2011","journal-title":"Transplant Proc"},{"key":"10.1016\/j.healun.2025.08.023_bib2","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1097\/TP.0000000000005374","article-title":"The Fourth International Consensus guidelines on the management of cytomegalovirus in solid organ transplantation","volume":"109","author":"Kotton","year":"2025","journal-title":"Transplantation"},{"key":"10.1016\/j.healun.2025.08.023_bib3","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1016\/j.healun.2024.05.010","article-title":"International Society for Heart and Lung Transplantation guidelines for the evaluation and care of cardiac transplant Candidates-2024","volume":"43","author":"Peled","year":"2024","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.healun.2025.08.023_bib4","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.transproceed.2008.02.048","article-title":"Leukopenia in kidney transplant patients with the association of valganciclovir and mycophenolate mofetil","volume":"40","author":"Brum","year":"2008","journal-title":"Transplant Proc"},{"key":"10.1016\/j.healun.2025.08.023_bib5","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1177\/1526924818765798","article-title":"Incidence and risk factors for leukopenia in kidney transplant recipients receiving valganciclovir for cytomegalovirus prophylaxis","volume":"28","author":"Liang","year":"2018","journal-title":"Prog Transplant"},{"key":"10.1016\/j.healun.2025.08.023_bib6","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1097\/01.ASN.0000079616.71891.F5","article-title":"Mycophenolate mofetil dose reduction and the risk of acute rejection after renal transplantation","volume":"14","author":"Knoll","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.healun.2025.08.023_bib7","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1111\/j.1399-0012.2008.00887.x","article-title":"Impact of dose reductions on efficacy outcome in heart transplant patients receiving enteric-coated mycophenolate sodium or mycophenolate mofetil at 12 months post-transplantation","volume":"22","author":"Segovia","year":"2008","journal-title":"Clin Transplant"},{"key":"10.1016\/j.healun.2025.08.023_bib8","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1093\/cid\/cix259","article-title":"Risk factors and outcomes of ganciclovir-resistant cytomegalovirus infection in solid organ transplant recipients","volume":"65","author":"Fisher","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.healun.2025.08.023_bib9","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.02684-21","article-title":"Detection of ganciclovir-resistant cytomegalovirus in a prospective cohort of kidney transplant recipients receiving subtherapeutic valganciclovir prophylaxis","volume":"10","author":"Wong","year":"2022","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.healun.2025.08.023_bib10","doi-asserted-by":"crossref","DOI":"10.1111\/tid.13634","article-title":"Factors associated with neutropenia post heart transplantation","volume":"23","author":"Chow","year":"2021","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.healun.2025.08.023_bib11","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1001\/jama.2023.9106","article-title":"Letermovir vs valganciclovir for prophylaxis of cytomegalovirus in high-risk kidney transplant recipients: a randomized clinical trial","volume":"330","author":"Limaye","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.healun.2025.08.023_bib12","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","article-title":"Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation","volume":"377","author":"Marty","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.healun.2025.08.023_bib13","doi-asserted-by":"crossref","DOI":"10.1111\/tid.13166","article-title":"Single-center experience with use of letermovir for CMV prophylaxis or treatment in thoracic organ transplant recipients","volume":"21","author":"Aryal","year":"2019","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.healun.2025.08.023_bib14","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.healun.2021.12.005","article-title":"Cytomegalovirus prevention in thoracic organ transplantation: a single-center evaluation of letermovir prophylaxis","volume":"41","author":"Saullo","year":"2022","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.healun.2025.08.023_bib15","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.14808","article-title":"Letermovir for cytomegalovirus prophylaxis in high-risk heart transplant recipients","volume":"36","author":"Golob","year":"2022","journal-title":"Clin Transplant"},{"key":"10.1016\/j.healun.2025.08.023_bib16","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.15327","article-title":"Real-life use of letermovir prophylaxis for cytomegalovirus in heart transplant recipients","volume":"38","author":"Saltiel","year":"2024","journal-title":"Clin Transplant"},{"key":"10.1016\/j.healun.2025.08.023_bib17","unstructured":"Letermovir. Rahway, NJ: Merck Sharp & Dohme LLC; 2021."},{"key":"10.1016\/j.healun.2025.08.023_bib18","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1093\/cid\/ciae321","article-title":"Consensus definitions of cytomegalovirus (CMV) infection and disease in transplant patients including resistant and refractory CMV for use in clinical trials: 2024 update from the Transplant Associated Virus Infections Forum","volume":"79","author":"Ljungman","year":"2024","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.healun.2025.08.023_bib19","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1093\/cid\/ciy295","article-title":"Absolute lymphocyte count: a predictor of recurrent cytomegalovirus disease in solid organ transplant recipients","volume":"67","author":"Gardiner","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.healun.2025.08.023_bib20","unstructured":"Rahman A., Lee C., Rahman\u00a0S. et al. Efficacy of letermovir for cytomegalovirus prophylaxis in heart transplant recipients with moderate to high-risk CMV serostatus J Card Fail in press."},{"key":"10.1016\/j.healun.2025.08.023_bib21","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.1016\/j.transproceed.2014.08.043","article-title":"Incidence, risk factors, and outcomes of delayed-onset cytomegalovirus disease in a large, retrospective cohort of heart transplant recipients","volume":"46","author":"Santos","year":"2014","journal-title":"Transplant Proc"}],"container-title":["The Journal of Heart and Lung Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053249825022570?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053249825022570?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T07:07:44Z","timestamp":1773126464000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1053249825022570"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S1053249825022570"],"URL":"https:\/\/doi.org\/10.1016\/j.healun.2025.08.023","relation":{},"ISSN":["1053-2498"],"issn-type":[{"value":"1053-2498","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tolerability and clinical efficacy of letermovir for primary cytomegalovirus prophylaxis after heart transplantation","name":"articletitle","label":"Article Title"},{"value":"The Journal of Heart and Lung Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.healun.2025.08.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Society for Heart and Lung Transplantation. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}